This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Poole, E. M. Articles by Ulrich, C. M. Search for Related Content PubMed PubMed Citation Articles by Poole, E. M. Articles by Ulrich, C. M.

Prostacyclin Synthase and Arachidonate 5-Lipoxygenase Polymorphisms and Risk of Colorectal Polyps

¹ Fred Hutchinson Cancer Research Center and ² Department of Epidemiology, University of Washington, Seattle, Washington

Requests for reprints: Cornelia Ulrich, Cancer Prevention Program, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M4-B402, Seattle, WA 98109-1024. Phone: 206-667-7617; Fax: 206-667-7850. E-mail: nulrich{at}fhcrc.org

Prostacyclin synthase (PGIS) and arachidonate 5-lipoxygenase (ALOX5) are enzymes relevant to prostaglandin and leukotriene synthesis, both important pathways for colon cancer risk. We hypothesized that genetic variation altering the function of these enzymes would modify risk of colorectal polyps. In a Minnesota-based case-control study of adenomatous (n = 517) or hyperplastic (n = 192) polyps versus polyp-free controls (n = 618), we investigated the role of promoter repeat polymorphisms in PGIS and ALOX5 as well as ALOX5 –1700 G>A. Having fewer than six repeats on both PGIS alleles (<6R/<6R) was associated with an increased risk of adenomas compared with the 6R/6R (wild-type) genotype (OR, 1.90; 95% CI, 1.09-3.30). Having more repeats (>6R/6R) reduced risk (OR, 0.73; 95% CI, 0.40-1.35; P_trend = 0.03). In allele-based analyses, fewer repeats were associated with a modestly increased risk of adenomas and perhaps hyperplastic polyps. There were no risk differences for either the ALOX5 VNTR or –1700 G>A polymorphisms. Associations with regular use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) differed by PGIS genotype. Among individuals with at least one wild-type allele, NSAID use was associated with a decreased risk; however, those with fewer PGIS repeats (<6R/<6R) did not benefit (P_interaction = 0.06). There was also evidence of an interaction between the COX-2 –765 G>C and ALOX5 –1700 G>A genotypes (P_interaction = 0.07). The PGIS promoter polymorphism may affect risk of colorectal polyps and modify the effects of NSAID use on polyp risk. A more comprehensive investigation of genetic variability in prostaglandin synthesis in relation to risk of colorectal neoplasia and NSAID pharmacogenetics is warranted. (Cancer Epidemiol Biomarkers Prev 2006;15(3):502–8)

This article has been cited by other articles:

				G. Andreotti, J. Chen, Y.-T. Gao, A. Rashid, B. E. Chen, P. Rosenberg, L. C. Sakoda, J. Deng, M.-C. Shen, B.-S. Wang, et al. Polymorphisms of Genes in the Lipid Metabolism Pathway and Risk of Biliary Tract Cancers and Stones: A Population-Based Case-Control Study in Shanghai, China Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 525 - 534. [Abstract] [Full Text] [PDF]

				M. L. Neuhouser, M. J. Barnett, A. R. Kristal, C. B. Ambrosone, I. King, M. Thornquist, and G. Goodman (n-6) PUFA Increase and Dairy Foods Decrease Prostate Cancer Risk in Heavy Smokers J. Nutr., July 1, 2007; 137(7): 1821 - 1827. [Abstract] [Full Text] [PDF]

				W. Tan, J. Wu, X. Zhang, Y. Guo, J. Liu, T. Sun, B. Zhang, D. Zhao, M. Yang, D. Yu, et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer Carcinogenesis, June 1, 2007; 28(6): 1197 - 1201. [Abstract] [Full Text] [PDF]

				E. M. Poole, J. Bigler, J. Whitton, J. G. Sibert, R. J. Kulmacz, J. D. Potter, and C. M. Ulrich Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps Carcinogenesis, June 1, 2007; 28(6): 1259 - 1263. [Abstract] [Full Text] [PDF]

				E. L. R. Barry, J. A. Baron, S. Bhat, M. V. Grau, C. A. Burke, R. S. Sandler, D. J. Ahnen, R. W. Haile, and T. G. O'Brien Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. J Natl Cancer Inst, October 18, 2006; 98(20): 1494 - 1500. [Abstract] [Full Text] [PDF]